Cerevel Therapeutics Holdings Interest Expense 2011-2026 | CERE

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Cerevel Therapeutics Holdings

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
10.6 M	3.92 M	-5.39 M	-3.27 M	-46.4 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
10.6 M	-46.4 M	-8.12 M

Quarterly Interest Expense Cerevel Therapeutics Holdings

2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
2.65 M	-	2.64 M	2.64 M	2.64 M	-	1.29 M	1.87 M	3.94 M	-	-7.54 M	-2.74 M	-425 K	-	-4.68 M	8.42 M	-15.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
8.42 M	-15.7 M	-386 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Aquestive Therapeutics AQST	6.55 M	$ 4.12	-0.36 %	$ 441 M	USA
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Arcturus Therapeutics Holdings ARCT	10.1 M	$ 8.32	3.67 %	$ 228 M	Israel
Arcutis Biotherapeutics ARQT	443 K	$ 23.65	0.08 %	$ 3.01 B	USA
BioVie BIVI	4.3 M	$ 1.46	2.82 %	$ 2.16 M	USA
BioLineRx Ltd. BLRX	9.07 M	$ 2.32	4.98 %	$ 908 M	Israel
BioNTech SE BNTX	14.2 M	$ 91.44	0.29 %	$ 27.2 B	Germany
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
BioXcel Therapeutics BTAI	-3.52 M	$ 1.16	-2.12 %	$ 14.2 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Cabaletta Bio CABA	2 M	$ 3.1	4.56 %	$ 311 M	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 3.17	1.44 %	$ 6.9 B	Israel
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Catalyst Biosciences CBIO	-1.5 M	$ 19.48	0.39 %	$ 1.74 B	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Codexis CDXS	-4.81 M	$ 1.95	6.87 %	$ 170 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	48 K	-	10.36 %	$ 9.8 M	USA
Anavex Life Sciences Corp. AVXL	4.68 M	$ 3.01	0.67 %	$ 257 M	USA
Cerus Corporation CERS	3.02 M	$ 1.91	2.69 %	$ 364 M	USA
Cullinan Management CGEM	-443 K	$ 15.11	4.71 %	$ 910 M	USA
Coherus BioSciences CHRS	9 M	$ 1.72	-0.87 %	$ 201 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
CNS Pharmaceuticals CNSP	7.03 K	$ 2.25	-0.44 %	$ 998 K	USA
Catalyst Pharmaceuticals CPRX	25.7 M	$ 24.95	1.05 %	$ 3.05 B	USA
Celldex Therapeutics CLDX	927 K	$ 31.33	0.85 %	$ 2.08 B	USA
Corbus Pharmaceuticals Holdings CRBP	1.24 M	$ 10.27	0.98 %	$ 137 M	USA
Cardiff Oncology CRDF	5 K	$ 1.6	1.27 %	$ 107 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA